In2Pharma
  • Home
  • Services
    • Regulatory Affairs
    • Quality Assurance
    • Publicity and Compliance
    • Medical writing & training
    • Vigilance
  • About Us
  • News
  • Contact
Select Page
Register your Industry Single Point of Contact (i-SPOC) on supply and availability

Register your Industry Single Point of Contact (i-SPOC) on supply and availability

by In2Pharma | Jul 5, 2022 | News

Europe All Marketing authorisation holders (MAHs) should register their Industry Single Point of Contact (i-SPOC) who will inform EMA about the supply and availability of critical medicines identified in the context of a ‘public health emergency’ or a ‘major event’...
Notifying a change of marketing status for centralized procedures

Notifying a change of marketing status for centralized procedures

by In2Pharma | Sep 3, 2021 | News

Europe On 26 July 2021, EMA has launched the IRIS platform, a secure online platform to report marketing status changes and withdrawn product notifications of centrally authorised medicinal products (CAPs) to EMA.The marketing status overview will provide to EMA and...

Recent Posts

  • Update Belgian FAQ on nutrition and health claims
  • Simplification of disclaimers for promotional materials
  • REACH Microplastics Restriction: What You Need to Know – and Do – Today!
  • “Successive GMP certificate” applications
  • New contact form for questions on variations and renewals from 1 June 2025

Follow Us

  • Facebook
  • LinkedIn
Privacy Policy | Cookie Policy | BTW BE 895730662 | +32 16 89 16 00| info@in2pharma.com | Terloonststraat 22, 1910 Kampenhout, België